Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biophytis ADR Representing 4000 Ord Shs BPTSY

Healthcare Biotechnology
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory... see more

Recent & Breaking News (OTCPK:BPTSY)

Biophytis Launches a Round of Fundraising for Approximately 2 Million Euros

Accesswire May 10, 2023

Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19

Accesswire May 9, 2023

Biophytis Strengthens its Management Team

Accesswire May 2, 2023

Biophytis Announces Receipt of Nasdaq Notice

Accesswire April 28, 2023

Biophytis Regains Compliance with NASDAQ Minimum Bid Price Requirement

Accesswire April 19, 2023

Biophytis Announces 2022 Financial Results and 2023 Perspectives

Accesswire April 18, 2023

Biophytis: Results of the Combined General Meeting on April 17, 2023

Accesswire April 18, 2023

Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023

Accesswire March 30, 2023

Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea

Accesswire March 27, 2023

Biophytis Announces Ratio Change Under its American Depositary Receipt ("ADR") Program

Accesswire March 17, 2023

Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference

Accesswire March 9, 2023

Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19

Accesswire March 2, 2023

Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19

Accesswire February 27, 2023

Biophytis To Host a Combined General Shareholder's Meeting on March 30, 2023

Accesswire February 23, 2023

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Accesswire February 2, 2023

Biophytis Publishes its Financial Results for the First Half of 2022

Accesswire January 31, 2023

Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Accesswire January 19, 2023

Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Accesswire January 12, 2023

Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed

Accesswire January 5, 2023

Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure

Accesswire December 1, 2022